John Kelly, MD, FRCS, joins The Uromigos to give an overview of a recent paper published in JAMA, “Effect of Robot-Assisted Radical Cystectomy With Intracorporeal Urinary Diversion vs Open Radical Cystectomy on 90-Day Morbidity and Mortality Among Patients With Bladder Cancer: A Randomized Clinical Trial.” The paper describes the benefits of robotic surgery compared with open cystectomy. ...
The Uromigos
The Uromigos, Thomas Powles, MD, and Brian Rini, MD, FASCO, highlight the latest developments in genitourinary cancers. Each podcast episode features a guest expert from around the world discussing the latest data, debates, and manuscripts relevant to the practical clinical care of GU oncology patients.
Get exclusive coverage of The Uromigos Live & Unplugged in Nashville, Tennessee, September 30 through October 1, including access to 3 livestream panel discussions.
Advertisement
Latest Episode
Advertisement
Uromigos: Live and Unplugged, a first-ever, in-person event, will take place in Nashville from September 30 to October 1.
Cora Sternberg, MD, discusses her career that has spanned multiple continents.
Bernard Escudier, MD, joins The Uromigos to talk about his career development and work in the field of kidney cancer.
Alex Wyatt joins The Uromigos to answer questions about ctDNA in prostate cancer and discuss his latest paper on that topic.
Declan Murphy and Matt Cooperberg debate the use of interventions in active surveillance for patients with prostate cancer.
Dr. Oliver Sartor, medical director of Tulane Cancer Center, discusses his career development and work in prostate cancer.
ESMO Coverage
Dr. Naveed Vasudev discusses IPI dosing and findings from the PRISM study.
Dr. Sarmad Sadeghi discusses exciting data about a novel compound in urothelial cancer with Brian and Tom.
Dr. Cora Sternber discusses AMG 160 and the future of immunotherapy in CRPC.
Chris Sweeney discusses the ATK inhibitor Ipatercertib in pTEN altered CRPC, a positive R3 trial in the ESMO plenary session.
Dr. Richard Cathomas goes into the detail of chemo immune combinations and what to do next.
Dr. Toni Choueiri and the Uromigos attempt to put the data into context with the other available combinations.
Paper of the Month
Yelena Janjigian describes ipi/nivo versus nivo chemo versus chemo in gastric cancer.
Syed Hussein and Sam Funt describe their studies on this topic.
Martin Stockler describes the ENZAMET trial, which shows mixed effects of enza on QOL in prostate cancer.
Elizabeth de Vries describes her paper on this topic published in Annals of Oncology.
Chad Tang discusses his oncology paper recently published in Lancet.
Dr. Samra Turajlic describes her paper on clear cell renal cell carcinoma.
Dr. Brian Rini’s Disclosures
Research Funding to Institution: Pfizer, Hoffman-LaRoche, Incyte, AstraZeneca, Taris, Seattle Genetics, Arrowhead Pharmaceuticals, Immunomedics, BMS, Mirati Therapeutics, Merck, Surface Oncology, Dragonfly Therapeutics, Aravive, Exelixis
Consulting: BMS, Pfizer, GNE/Roche, Aveo, Synthorx, Compugen, Merck, Corvus, Surface Oncology, 3DMedicines, Aravive, Alkermes, Arrowhead, GSK, Shionogi, Eisai
Stock: PTC therapeutics
Advertisement
Advertisement
